Creative Medical Technology Holdings, Inc. focuses on developing regenerative medicine & immunotherapies that seek to improve patient outcomes & quality of living.
Type 1 diabetes is a chronic autoimmune disease leading to the destruction of insulin producing cells within the pancreas. Autoreactive T cells and abnormalities in immune regulation, especially in regulatory T cells, are thought to play a key role in disease development. Chronic autoimmune T cell attacks against the pancreatic cells are considered the primary cause of type 1 diabetes. These attacks on pancreatic cells lead to the loss of the ability to produce insulin and in turn creates a life-long dependence on insulin injections.
There currently is no cure for type 1 diabetes. The disease is treated with regular insulin injections and close blood glucose monitoring. Despite the advances in insulin therapy, many patients still suffer from hypo- and hyperglycemia. Also, insulin therapy can potentially be very expensive, making it an even more difficult disease to manage.
In the United States alone, approximately 1.3 million people, especially children and adolescents, suffer from type 1 diabetes. The incidence of type 1 diabetes continues to increase in many countries. The disease severely impacts quality of life and leads to both acute and chronic complications, such as end stage renal disease, blindness, cardiovascular disease, diabetic ketoacidosis and hypoglycemia. The economic burden caused by type 1 diabetes amounts to approximately $14.4 billion in medical costs and lost income.
Interested in learning more?
Connect with us now by filling out our form on our contact page.